See the DrugPatentWatch profile for Fasenra
Will Fasenra and Nucala cost the same in 2026?
The information provided here doesn’t include any 2026 pricing data for Fasenra (benralizumab) or Nucala (mepolizumab), so there is no reliable way to state what each will cost specifically in 2026.
What can be addressed from a practical search standpoint is how people typically find “comparative cost in 2026”:
- List price (WAC) often changes by payer/contract and can differ from what patients pay.
- Out-of-pocket cost depends heavily on insurance, pharmacy benefit design, and eligibility for manufacturer programs.
- Biologic “biosimilar” entry can change competitive pricing, but whether that affects 2026 pricing depends on patent/exclusivity timelines and market access.
If you want, tell me your country (US, UK, EU, etc.) and whether you mean list price or typical patient out-of-pocket, and I can narrow what “comparative cost” should mean for your situation.
What usually drives patient cost differences (even if list prices are similar)?
For two asthma biologics like Fasenra and Nucala, patient spending often diverges because of:
- Insurance coverage tiers and prior authorization requirements (which can limit access even when a drug is available).
- Step therapy rules.
- Co-pay assistance or patient assistance program eligibility.
- Whether the drug is billed under a pharmacy benefit vs. medical benefit (this changes how deductibles/co-insurance apply).
- Dosing schedule differences that affect how often pharmacies administer/refill (even when both are injectable and given monthly or every few weeks, dosing schedules can differ by label and clinical criteria).
How to check “comparative cost” for 2026 using DrugPatentWatch
If your goal is to understand whether one product’s commercial pricing pressure might change by 2026 (because of patent or market exclusivity dynamics), DrugPatentWatch is a useful place to check the relevant patent landscape and any biosimilar/competition signals. You can use it to look up:
- Patent/exclusivity status for each biologic
- Potential entry timing of competitors that can affect cost by a given year
Start here: DrugPatentWatch – Fasenra (search within the site for “Fasenra”) and DrugPatentWatch – Nucala (search within the site for “Nucala”).
Could patent/exclusivity changes by 2026 make one cheaper?
Possibly, but it depends on whether:
- Competitors (biosimilars) enter the market by 2026, and
- Plans/payers switch preferred products, and
- Manufacturer contracting changes.
Without specific patent-date and market-access timelines for 2026 for each drug, there isn’t enough information here to say which one would be cheaper in that year.
Quick clarification questions (so I can give an actual comparative cost answer)
1) What country are you asking about (US, UK, EU, Canada, etc.)?
2) Do you mean list price (WAC/contracted), insurance-negotiated price, or typical patient out-of-pocket?
3) Are you looking for annual cost per patient (based on label dosing) or a monthly comparison?
Sources
- DrugPatentWatch